sk&f 82958 has been researched along with Dyskinesia, Medication-Induced in 7 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Ritanserin pretreatment blunted systemic SKF 82958-induced hyperlocomotion and returned intrastriatal D1-mediated hyperactivity to sham lesion levels." | 1.32 | Intrastriatal serotonin 5-HT2 receptors mediate dopamine D1-induced hyperlocomotion in 6-hydroxydopamine-lesioned rats. ( Bishop, C; Kamdar, DP; Walker, PD, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (42.86) | 18.2507 |
| 2000's | 3 (42.86) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Scheggi, S | 1 |
| Rossi, F | 1 |
| Corsi, S | 1 |
| Fanni, S | 1 |
| Tronci, E | 1 |
| Ludovica, C | 1 |
| Vargiu, R | 1 |
| Gambarana, C | 1 |
| Muñoz, A | 1 |
| Stancampiano, R | 1 |
| Björklund, A | 1 |
| Carta, M | 1 |
| Bishop, C | 1 |
| Kamdar, DP | 1 |
| Walker, PD | 1 |
| Samadi, P | 1 |
| Grégoire, L | 1 |
| Bédard, PJ | 4 |
| Blanchet, PJ | 3 |
| Grondin, R | 3 |
| Goulet, M | 2 |
| Di Paolo, T | 2 |
| Andringa, G | 1 |
| Lubbers, L | 1 |
| Drukarch, B | 1 |
| Stoof, JC | 1 |
| Cools, AR | 1 |
| Calon, F | 1 |
| Morissette, M | 1 |
7 other studies available for sk&f 82958 and Dyskinesia, Medication-Induced
| Article | Year |
|---|---|
BDNF Overexpression Increases Striatal D3 Receptor Level at Striatal Neurons and Exacerbates D1-Receptor Agonist-Induced Dyskinesia.
Topics: Animals; Benzazepines; Brain-Derived Neurotrophic Factor; Corpus Striatum; Disease Models, Animal; D | 2020 |
Intrastriatal serotonin 5-HT2 receptors mediate dopamine D1-induced hyperlocomotion in 6-hydroxydopamine-lesioned rats.
Topics: Animals; Benzazepines; Denervation; Dopamine; Dopamine Agonists; Drug Interactions; Dyskinesia, Drug | 2003 |
Opioid antagonists increase the dyskinetic response to dopaminergic agents in parkinsonian monkeys: interaction between dopamine and opioid systems.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Benzazepines; Dopamine; Dopamine Agents; Dopa | 2003 |
Dyskinesia and wearing-off following dopamine D1 agonist treatment in drug-naive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned primates.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Benzazepines; Brain; Dopamine Agents; Dopamin | 1996 |
Dyskinesias and tolerance induced by chronic treatment with a D1 agonist administered in pulsatile or continuous mode do not correlate with changes of putaminal D1 receptors in drug-naive MPTP monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Benzazepines; Catecholamines; Dopamine Agonis | 1996 |
The predictive validity of the drug-naive bilaterally MPTP-treated monkey as a model of Parkinson's disease: effects of L-DOPA and the D1 agonist SKF 82958.
Topics: Animals; Antiparkinson Agents; Arm; Behavior, Animal; Benzazepines; Dopamine Agents; Dopamine Agonis | 1999 |
125I-CGP 64213 binding to GABA(B) receptors in the brain of monkeys: effect of MPTP and dopaminomimetic treatments.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Autoradiography; Basal | 2000 |